Alectinib halts lung cancer growth more than a year longer than crizotinib
Monday, June 5, 2017 - 11:12
in Health & Medicine
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects.